Founded on a breakthrough discovery
We develop innovative therapies for auto-immune diseases, based on a breakthrough discovery demonstrating that CXCR4 is a master regulator of inflammation.
type I interferon-driven Auto Immune Diseases
Ermium first in class therapeutics address type I interferon-driven diseases including Systemic lupus erythematosus, Dermatomyositis, Sjorgen’s Syndrome, Monogenic interferonopathies.
Ermium Therapeutics was founded in June 2019 by Jean-Philippe HERBEUVAL, Kurma Partners, Domain Therapeutics and Erganeo. Since, we haven’t ceased to welcome new partners.